Syndax’s leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in multiple acute leukemia subtypes across the R/R, frontline, and post-HSCT setting – ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...

Terns Pharmaceuticals ( ($TERN) ) has shared an announcement. On November 3, 2025, Terns Pharmaceuticals announced that data from the Phase 1 ...

Accurate, reliable results play a role in free and fair elections. So does explaining the data and helping people understand ...

Deutsche Telekom is making a major push into artificial intelligence (AI) infrastructure, teaming up with US chipmaker Nvidia ...

Two oral and seven poster presentations further support the CARVYKTI® research in multiple myeloma First-in-Human Phase 1 ...

Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use - SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc.

The poster presentation will be available on the Aptose website here.

"This year’s Incyte presentations highlight the potential of our portfolio to transform the treatment of blood cancers, specifically for patients with myeloproliferative neoplasms," said Pablo J.

An announcement from AML3D Ltd ( ($AU:AL3) ) is now available. AML3D Limited has released a disclaimer regarding the information contained in its ...